A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus (ATTAIN I & ATTAIN II)

Phase 3

Completed

• Conditions: Hospital-Acquired Pneumonia; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12605000324617
• Lead Sponsor: Theravance, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 750

Inclusion Criteria

Diagnosis of hospital acquired pneumonia.

Exclusion Criteria

More than 24 hours of prior therapy unless a treatment failure. Pregnancy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical response at test of cure evaluation[Performed 7 to 14 days following completion of treatment]

Secondary Outcome Measures

Name	Time	Method
Safety and tolerability[Baseline, q 3d, End of Therapy and Test of Cure]